FDA Approves Oral Pellet Formulation of BioCryst's Orladeyo
BioCryst Pharmaceuticals (BCRX) has received FDA approval for a new oral pellet formulation of its leading product, Orladeyo. This regulatory milestone represents a label expansion for the once-daily therapy, which is used to treat hereditary angioedema (HAE), a rare genetic condition. The introduction of the oral pellet version aims to provide more flexibility in administration for patients managing HAE. As Orladeyo is currently BioCryst's bestselling product, this approval is expected to support continued market penetration and patient adherence within the U.S. orphan drug market.
Tickers: $BCRX